Psychological therapies versus pharmacological interventions for panic disorder with or without agoraphobia in adults

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 7, 2014, Pages

  Imai, Hissei ^a   Tajika, Aran ^a   Chen, Peiyao ^a   Pompoli, Alessandro ^b   Furukawa, Toshi A ^a  

^a KYOTO UNIVERSITY SCHOOL OF PUBLIC HEALTH   (Japan)

^b UNIVERSITY OF VERONA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; HETEROCYCLIC ANTIDEPRESSANT AGENT; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; REBOXETINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG;

ADULT; AGE DISTRIBUTION; AGORAPHOBIA; BEHAVIOR THERAPY; BREATHING EXERCISE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL PROTOCOL; COGNITIVE BEHAVIORAL THERAPY; COGNITIVE THERAPY; COMORBIDITY; DRUG EFFICACY; HUMAN; INTERMETHOD COMPARISON; OUTCOME ASSESSMENT; PANIC; PATIENT SAFETY; PATIENT SELECTION; PRIORITY JOURNAL; PSYCHODYNAMIC PSYCHOTHERAPY; PSYCHOEDUCATION; PSYCHOPHARMACOTHERAPY; PSYCHOTHERAPY; RELAXATION TRAINING; REMISSION; REVIEW; SYSTEMATIC REVIEW; THERAPY EFFECT; TREATMENT RESPONSE;

EID: 85041501156     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD011170     Document Type: Review

References (72)

1. Altman DG, Bland MJ. Detecting skewness for summary information. BMJ 1996;313(7066):1200.
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 3rd Edition. American Psychiatric Association, 1980.
3. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 3rd Edition. American Psychiatric Association, 1987.
4. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th Edition. American Psychiatric Association, 2000.
5. American Psychiatric Association. American Psychiatric Association Practice Guidelines for the Treatment of Panic Disorder. American Psychiatric Publishing, 2009.
6. Bandelow B. Assessing the efficacy of treatments for panic disorder and agoraphobia. II. The Panic and Agoraphobia Scale. International Clinical Psychopharmacology 1995;10(2):73-81.
7. Bald win DS, Anderson IM, Nutt DJ, Bandelow B, Bond A, Davidson JR, et al.Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology 2005;19(6):567-96.
8. Barlow DH. Anxiety and Its Disorders. Guilford Press, 1988.
9. Baudry A, Mouillet-Richard S, Launay J, Kellermann O. New view on antidepressant action. Current Opinion in Neurobiology 2011;21(6):858-65.
10. Beck AT, Epstein N, Brown G, Steer RA. An inventory for measuring clinical anxiety: psychometric properties. Journal of Consulting and Clinical Psychology 1988;56(6):893-7.
11. Bijl RV, Ravelli A, van Zessen G. Prevalence of psychiatric disorder in the general population: results of The Netherlands Mental Health Survey and Incidence Study (NEMESIS). Social Psychiatry and Psychiatric Epidemiology 1998;33(6):683-91.
12. Bradwejn J, Ahokas A, Stein DJ, Salinas E, Emilien G, Whitaker T. Venlafaxine extended-release capsules in panic disorder: flexible-dose, double-blind, placebo-controlled study. British Journal of Psychiatry 2005;187:352-9.
13. Chambless DL, Caputo GC, Bright P, Gallagher R. Assessment of fear of fear in agoraphobics: The Body Sensations Questionnaire and the Agoraphobic Cognitions Questionnaire. Journal of Consulting and Clinical Psychology 1984;52(6):1090-7.
14. Chambless DL, Caputo GC, Jasin SE, Gracely EJ, Williams C. The Mobility Inventory for Agoraphobia. Behaviour Research and Therapy 1985;23(1):36-44.
15. Clum GA, Surls R. A meta-analysis of treatments for panic disorder. Journal of Consulting and Clinical Psychology 1993;61(2):317-26.
16. Comer JS, Blanco C, Hasin DS, Liu SM, Grant BF, Turner JB, et al.Health-related quality of life across the anxiety disorders. Journal of Clinical Psychiatry 2011;72(1):43-50.
17. Daele T, Hermans D, Audenhove C, Bergh O. Stress reduction through psychoeducation: a meta-analytic review. Health Education & Behavior 2012;39(4):474-85.
18. Deacon B, Abramowitz J, Woods C, Tolin D. The Anxiety Sensitivity Index - Revised: psychometric properties and factor structure in two nonclinical samples. Behaviour Research and Therapy 2003;41(12):1427-49.
19. Douglas C. Teaching supportive psychotherapy to psychiatric residents. American Journal of Psychiatry 2008;165(4):445-52.
20. Eaton WW, Kessler RC, Wittchen HU, Magee WJ. Panic and panic disorder in the United States. American Journal of Psychiatry 1994;151:413-20.
21. Eldridge FL, Millhorn DE. Central regulation of respiration by endogenous neurotransmitters and neuromodulators. Annual Review of Physiology 1981;43:121-35.
22. Endicott J, Spitzer RL, Fleiss JL, Cohen J. The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance. Archives of General Psychiatry 1976;33(6):766-71.
23. Feighner JP, Robins E, Guze SB, Woodruff RA, Winokur G, Munoz R. Diagnostic criteria for use in psychiatric research. Archives of General Psychiatry 1972;26(1):57-63.
24. Freire RC, Hallak JE, Nardi AE. New treatment options for panic disorder: clinical trials from 2000 to 2010. Expert Opinion Pharmacotherapy 2011;12(9):1419-28.
25. Furukawa TA, Guyatt GH, Griffith LE. Can we individualize the 'number needed to treat'? An empirical study of summary effect measures in meta-analyses. International Journal of Epidemiology 2002;31(1):72-6.
26. Furukawa TA, Cipriani A, Barbui C, Brambilla P, Watanabe N. Imputing response rates from means and standard deviations in meta-analysis. International Clinical Psychopharmacology 2005;20(1):49-52.
27. Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N. Imputing missing standard deviations in meta-analyses can provide accurate results. Journal of Clinical Epidemiology 2000;59(1):7-10.
28. Furukawa TA, Watanabe N, Churchill R. Combined psychotherapy plus antidepressants for panic disorder with or without agoraphobia. Cochrane Database of Systematic Reviews 2007, Issue 1. [DOI: 10.1002/14651858.CD004364.pub2].
29. Goldapple K, Segal Z, Garson C, Lau M, Bieling P, Kennedy S, et al.Modulation of cortical-limbic pathways in major depression treatment-specific effects of cognitive behavior therapy. Archives of General Psychiatry 2004;61(1):34-41.
30. Gould RA, Otto MW, Pollack MH. A meta-analysis of treatment outcome for panic disorder. Clinical Psychology Review 1995;15(8):819-44.
31. Grant BF, Hasin DS, Stinson FS, Dawson DA, Goldstein RB, Smith S, et al.The epidemiology of DSM-IV panic disorder and agoraphobia in the United States: result from the National Epidemiologic Survey on Alcohol and Related Conditions. Journal of Clinical Psychiatry 2006;67:363-74.
32. Guy W. Clinical Global Impression. ECDEU Assessment Manual for Psychopharmacology, revised. National Institute of Mental Health, 1976:218-22.
33. Hamilton M. The assessment of anxiety states by rating. British Journal of Medical Psychology 1959;32(1):50-5.
34. Hayes S. Acceptance and commitment therapy, relational frame theory, and the third wave of behavioral and cognitive therapies. Behaviour Therapy 2004;35(4):639-65.
35. Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60.
36. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
37. James A, James G, Cowdrey F, Soler A, Choke A. Cognitive behavioural therapy for anxiety disorders in children and adolescents. Cochrane Database of Systematic Reviews 2013, Issue 6. [DOI: 10.1002/14651858.CD004690.pub3].
38. Kahl KG, Winter L, Schweiger U. The third wave of cognitive behavioural therapies: what is new and what is effective?. Current Opinion in Psychiatry 2012;25(6):522-8.
39. Kessler RC, Chiu WT, Jin R, Ruscio AM, Shear K, Walters EE. The epidemiology of panic attacks, panic disorder, and agoraphobia in the National Comorbidity Survey Replication. Archives of General Psychiatry 2006;63:415-24.
40. Kind P. The EuroQol instrument: an index of health related quality of life. In: Spilker B editor(s). Quality of Life and Pharmacoeconomics in Clinical Trials. 2nd Edition. Philadelphia: Lippincott-Raven Publishers, 1996:191-201.
41. King M, Nazareth I, Levy G, Walker C, Morris R, Weich S, et al.Prevalence of common mental disorders in general practice attendees across Europe. British Journal of Psychiatry 2008;192(5):362-7.
42. Klein DF. False suffocation alarms, spontaneous panics, and related conditions. An integrative hypothesis. Archives of General Psychiatry 1993;50(4):306-17.
43. Malizia AL, Cunningham VJ, Bell CJ, Liddle PF, Jones T. Decreased brain GABAA-benzodiazepine receptor binding in panic disorder preliminary results from a quantitative PET study. Archives of General Psychiatry 1998;55(8):715-20.
44. Markowitz JS, Weissman MM, Ouellette R, Lish JD, Klerman GL. Quality of life in panic disorder. Archives of General Psychiatry 1989;46(11):984-92.
45. Marks IM, Mathew AM. Brief standard self-rating for phobic patients. Behavior Research and Therapy 1979;17(3):263-7.
46. Marks IM. Cure and Care of Neuroses: Theory and Practice of Behavioural Psychotherapy. New York: Wiley, 1981.
47. Mauret AE, Ritz T. Hyperventilation in panic disorder and asthma: empirical evidence and clinical strategies. International Journal of Psychophysiology 2010;78(1):68-79.
48. Mayberg HS, Liotti M, Brannan SK, McGinnis S, Mahurin RK, Jerabek PA, et al.Reciprocal limbic-cortical function and negative mood: converging PET findings in depression and normal sadness. American Journal of Psychiatry 1999;156:675-82.
49. Mayberg HS, Brannan SK, Tekell JL, Silva JA, Mahurin RK, McGinnis S, et al.Regional metabolic effects of fluoxetine in major depression: serial changes and relationship to clinical response. Biological Psychiatry 2000;48:830-43.
50. Michelson D, Lydiard RB, Pollack MH, Tamura RN, Hoog SL, Tepner R, et al.Outcome assessment and clinical improvement in panic disorder: evidence from a randomized controlled trial of fluoxetine and placebo. American Journal of Psychiatry 1998;155(11):1570-7.
51. Milrod B, Leon AC, Busch F, Rudden M, Schwalberg M, Clarkin J, et al.A randomized controlled clinical trial of psychoanalytic psychotherapy for panic disorder. American Journal of Psychiatry 2007;164(2):265-72.
52. Mitte K. A meta-analysis of the efficacy of psycho- and pharmacotherapy in panic disorder with and without agoraphobia. Journal of Affective Disorders 2005;88(1):27-45.
53. National Institute for Health and Care Excellence. Generalised anxiety disorder and panic disorder (with or without agoraphobia) in adults: Management in primary, secondary and community care (CG113). London: National Institute for Health and Care Excellence 2011.
54. Ost L. Efficacy of the third wave of behavioral therapies: a systematic review and meta-analysis. Behaviour Research and Therapy 2008;46(3):296-321.
55. Ravindran LN, Stein MB. The pharmacologic treatment of anxiety disorders: a review of progress. Journal of Clinical Psychiatry 2010;71(7):839-54.
56. Reiss S, Peterson RA, Gursky DM, McNally RJ. Anxiety sensitivity, anxiety frequency, and the prediction of fearfulness. Behaviour Research and Therapy 1986;24(1):1-8.
57. Sadock BJ, Kaplan HI, Sadock VA (editors). Kaplan & Sadock's Synopsis of Psychiatry: Behavioral Sciences/Clinical Psychiatry. Lippincott Williams & Wilkins, 2003.
58. Sanchez-Meca J, Rosa-Alcazar AI, Marin-Martinez F, Gomez-Conesa A. Psychological treatment of panic disorder with or without agoraphobia: a meta-analysis. Clinical Psychology Review 2010;30(1):37-50.
59. Sareen J, Cox BJ, Afifi TO, Graaf RD, Asmundson GJG, Have TH, et al.Anxiety disorders and risk for suicidal ideation and suicide attempts. Archives of General Psychiatry 2005;62:1249-57.
60. Schotte C, Bossche B, Doncker D, Claes S, Cosyns P. A biopsychosocial model as a guide for psychoeducation and treatment of depression. Depression and Anxiety 2006;23(5):312-24.
61. Shear MK, Brown TA, Barlow DH, Money R, Sholomskas DE, Woods SE, et al.Multicenter collaborative panic disorder severity scale. American Journal of Psychiatry 1997;154(11):1571-5.
62. Sherbourne C, Sullivana G, Crasked MG, Roy-Byrnee P, Golinellia D, Rosed RD, et al.Functioning and disability levels in primary care outpatients with one or more anxiety disorders. Psychological Medicine 2010;40(12):2059-68.
63. Spielberger CD, Gorssuch RL, Lushene PR, Vagg PR, Jacobs GA. Manual for the State-Trait Anxiety Inventory. Consulting Psychologists Press, 1983.
64. Spitzer RL, Robins E. Research diagnostic criteria: rationale and reliability. Archives of General Psychiatry 1978;35(6):773-82.
65. Starcevic V. Anxiety Disorders in Adults: a Clinical Guide. Oxford University Press, 2009.
66. Swinson RP, Cox BJ, Woszczyna CB. Use of medical services and treatment for panic disorder with agoraphobia and for social phobia. Canadian Medical Association Journal 1992;147(6):878-83.
67. Teasdale JD, Moore RG, Hayhurst H, Pope M, Williams S, Segal ZV. Metacognitive awareness and prevention of relapse in depression: empirical evidence. Journal of Consulting and Clinical Psychology 2002;70(2):275-87.
68. Ware JE Jr, Sherbourne CD. The MOS 36-item short form health survey (SF-36) I. Conceptual framework and item selection. Medical Care 1992;30(6):473-83.
69. World Health Organization. The ICD-10 International Statistical Classification of Diseases and Health Related Problems. Geneva: World Health Organization, 1992.
70. Winston A, Rosenthal RN, Pinsker H. Introduction to Supportive Psychotherapy. Washington, DC: American Psychiatric Publication, 2004.
71. Wittchen HU. Generalized anxiety disorder: prevalence, burden, and cost to society. Depression and Anxiety 2002;16:162-71.
72. Zohar J, Westenberg HG. Anxiety disorders: a review of tricyclic antidepressants and selective serotonin reuptake inhibitors. Acta Psychiatrica Scandinavica. Supplementum 2000;403:39-49.